CBOE vs CME

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 23, 2026

CBOE

30.2
AI Score
VS
CME Wins

CME

32.8
AI Score

Investment Advisor Scores

CBOE

Oct 23, 2026
30score
Recommendation
AVOID NEW MONEY

CME

Oct 23, 2026
33score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric CBOE CME Winner
Forward P/E 21.9298 21.9298 Tie
PEG Ratio 2.3792 4.7092 CBOE
Revenue Growth 22.9% 0.8% CBOE
Earnings Growth 50.2% 2.5% CBOE
Tradestie Score 30.2/100 32.8/100 CME
Profit Margin 26.7% 63.4% CME
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation AVOID NEW MONEY AVOID NEW MONEY Tie

Relative Price Performance (Last 90 Days)

CBOE 1M: +21.9% · 3M: +15.0% CME 1M: +13.0% · 3M: +19.8%

Current Technical Phase

CBOE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 69

RSI (14): 69.1 · Price: $327.72

CME

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.0% over 20 days), RSI 78

RSI (14): 78.4 · Price: $305.98

Fundamentals Snapshot

Metric CBOE CME
Market Cap — —
Forward P/E 21.6 23.4
Trailing P/E 24.8 25.1
Revenue (TTM) — —
Revenue Growth 0.2% 0.0%
Gross Margin 0.5% 1.0%
Operating Margin 0.3% 0.7%
EPS 12.83 11.79
Dividend Yield 0.01% 0.02%

Frequently Asked Questions

Based on our detailed analysis, CME is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.